Risk-factors for re-admission and outcome of patients hospitalized with confirmed COVID-19.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
31 08 2021
Historique:
received: 15 12 2020
accepted: 12 08 2021
entrez: 1 9 2021
pubmed: 2 9 2021
medline: 14 9 2021
Statut: epublish

Résumé

Burden of COVID-19 on Hospitals across the globe is enormous and has clinical and economic implications. In this retrospective study including consecutive adult patients with confirmed SARS-CoV-2 who were admitted between 3/2020 and 30/9/20, we aimed to identify post-discharge outcomes and risk factors for re-admission among COVID-19 hospitalized patients. Mortality and re-admissions were documented for a median post discharge follow up of 59 days (interquartile range 28,161). Univariate and multivariate analyses of risk factors for re-admission were performed. Overall, 618 hospitalized COVID-19 patients were included. Of the 544 patient who were discharged, 10 patients (1.83%) died following discharge and 50 patients (9.2%) were re-admitted. Median time to re-admission was 7 days (interquartile range 3, 24). Oxygen saturation or treatment prior to discharge were not associated with re-admissions. Risk factors for re-admission in multivariate analysis included solid organ transplantation (hazard ratio [HR] 3.37, 95% confidence interval [CI] 2.73-7.5, p = 0.0028) and higher Charlson comorbidity index (HR 1.34, 95% CI 1.23-1.46, p < 0.0001). Mean age of post discharge mortality cases was 85.0 (SD 9.98), 80% of them had cognitive decline or needed help in ADL at baseline. In conclusion, re-admission rates of hospitalized COVID-19 are fairly moderate. Predictors of re-admission are non-modifiable, including baseline comorbidities, rather than COVID-19 severity or treatment.

Identifiants

pubmed: 34465827
doi: 10.1038/s41598-021-96716-7
pii: 10.1038/s41598-021-96716-7
pmc: PMC8408195
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

17416

Informations de copyright

© 2021. The Author(s).

Références

Int J Clin Pract. 2021 Mar;75(3):e13700
pubmed: 32894801
Am J Transplant. 2020 Jul;20(7):1849-1858
pubmed: 32301155
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Isr Med Assoc J. 2020 May;22(5):275-277
pubmed: 32378816
BMC Med. 2020 Sep 3;18(1):270
pubmed: 32878619
BMJ. 2020 Apr 7;369:m1328
pubmed: 32265220
Nature. 2020 Aug;584(7821):430-436
pubmed: 32640463
BMJ Open. 2018 Mar 30;8(3):e020243
pubmed: 29602852
Int J Infect Dis. 2020 Oct;99:229-230
pubmed: 32771639
JBI Database System Rev Implement Rep. 2016 Feb;14(2):106-73
pubmed: 27536797
Eur J Intern Med. 2012 Jul;23(5):457-60
pubmed: 22726376
J Infect. 2020 Sep;81(3):e18-e19
pubmed: 32652166
BMC Geriatr. 2016 May 12;16:102
pubmed: 27175921
Age Ageing. 2020 Jul 1;49(4):516-522
pubmed: 32725209
Int J Qual Health Care. 2021 Feb 20;33(1):
pubmed: 33104780
JAMA Netw Open. 2020 Jun 1;3(6):e2012270
pubmed: 32543702
Lancet Haematol. 2020 Sep;7(9):e671-e678
pubmed: 32659214
J Am Geriatr Soc. 2020 Jul;68(7):1376-1381
pubmed: 32441770
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
BMC Health Serv Res. 2017 May 16;17(1):355
pubmed: 28511702
Lancet. 2020 Jun 6;395(10239):1763-1770
pubmed: 32442528
Int J Environ Res Public Health. 2020 Aug 12;17(16):
pubmed: 32806775
BMC Geriatr. 2010 May 11;10:22
pubmed: 20459844
Nephrol Dial Transplant. 2020 Jul 1;35(7):1250-1261
pubmed: 32678882
Epidemiol Infect. 2018 Aug;146(11):1350-1358
pubmed: 29880077
J Eval Clin Pract. 2015 Aug;21(4):560-6
pubmed: 25756358
J Gen Intern Med. 2020 Oct;35(10):2838-2844
pubmed: 32815060
Am J Transplant. 2020 Jul;20(7):1800-1808
pubmed: 32330343
MMWR Morb Mortal Wkly Rep. 2020 Nov 13;69(45):1695-1699
pubmed: 33180754
MMWR Morb Mortal Wkly Rep. 2020 Jun 19;69(24):759-765
pubmed: 32555134
BMJ. 2020 Sep 9;370:m3339
pubmed: 32907855

Auteurs

Hefziba Green (H)

Department of Medicine B, Rabin Medical Center, Beilinson Campus, Jabutisky St 39, 4941492, Petah Tiqva, Israel. hefzigreen@gmail.com.
Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel. hefzigreen@gmail.com.

Dafna Yahav (D)

Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel.
Infectious Diseases Unit, Rabin Medical Center, Beilinson Campus, Petah Tiqva, Israel.

Noa Eliakim-Raz (N)

Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel.
Department of Medicine E, Rabin Medical Center, Beilinson Campus, Petah Tiqva, Israel.

Nitzan Karny-Epstein (N)

Department of Medicine B, Rabin Medical Center, Beilinson Campus, Jabutisky St 39, 4941492, Petah Tiqva, Israel.

Shiri Kushnir (S)

Research Authority, Rabin Medical Center, Beilinson Campus, Petah Tiqva, Israel.

Tzippy Shochat (T)

Bio-statistics Unit, Rabin Medical Center, Beilinson Campus, Petah Tiqva, Israel.

Boaz Tadmor (B)

Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel.

Alon Grossman (A)

Department of Medicine B, Rabin Medical Center, Beilinson Campus, Jabutisky St 39, 4941492, Petah Tiqva, Israel.
Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH